Tamtam Try Tamtam free
Aptar logo

Aptar account plan

Dosing dispensing protection technologies

At a glance

Aptar is a NYSE-listed maker of drug and consumer dispensing, dosing and protection systems with $3.78 billion 2025 sales and about 14,000 employees.

AptarGroup, Inc. (NYSE: ATR), headquartered in Crystal Lake, Illinois, designs and manufactures dispensing pumps, closures, aerosol valves, elastomeric components for injectables, active material science solutions and digital health solutions. It serves pharmaceutical, fragrance, skincare, cosmetics, food, beverage, personal care and home care customers, approximately 5,000 in all, with Europe at 49% of sales. FY2025 net sales rose 5% to $3.78 billion, with net income attributable to Aptar of $392.8 million and an Adjusted EBITDA margin of 21.6%. It has approximately 14,000 employees in approximately 20 countries.

Business units

Strategic priorities

Profitable growth over sales growth
The new CEO's priorities are profitable growth, execution and disciplined capital allocation, converting demand into more consistent profitability.
Pharma pipeline
Reaffirmed long-term Pharma core growth corridor of 7% to 11%, built on ophthalmic, nasal, inhalation and injectables programmes such as Beat the Blink with Bausch + Lomb, the PULMOTREE Kolibri liquid inhaler and the Premia Precision injectables standard.
Beauty North America turnaround
A diagnostic of North American Beauty is nearly complete; management describes a transformation of how it competes and executes that will take time.
Cost and ROIC management
Managing fixed costs and improving return on invested capital through Global Business Service Centers, among five strategic focus areas in the 10-K.
Sustainable packaging
SBTi-validated Scope 1, 2 and 3 targets, recyclable product lines, and low-carbon pMDI propellant work following the HFC phase-down.

Latest results

In Q3 2026 net sales rose 6% to $1.02 billion with core sales up 5% across all three segments. Adjusted EPS was $1.52, at the higher end of guidance, and the Adjusted EBITDA margin was 21.3% against 23.2%. Reported net income fell to $32.6 million after a $58.0 million loss on deconsolidating the Russian subsidiary. Over nine months sales were $3.03 billion (+8%) and adjusted EPS $4.13 (-10%), with emergency medicine sales expected down about $65 million in 2026. Q4 2026 adjusted EPS guidance is $1.39 to $1.47.

Investments and deals

Capital investments
Capex of $270.4 million in 2025 and expected at $260 million to $280 million in 2026, including Pharma expansion in Mumbai.
Acquisitions
Sommaplast for $27.0 million (December 2025), BTY raised to 80% for approximately $29.0 million (July 2025), 40% of Goldrain for approximately $99.0 million (October 2024), and PULMOTREE.
Shareholder returns
$485.8 million returned in 2025, a new $600.0 million buyback authorization in February 2026, and the quarterly dividend raised from $0.48 to $0.50.
Financing
$600.0 million of 4.75% Senior Notes due March 2031 issued in November 2025.

Challenges and risks

Emergency medicine decline
Naloxone (emergency medicine) sales fall about $65 million in 2026 as the product shifts to OTC and generics.
North American Beauty
Beauty margins fell on unfavourable mix and ongoing challenges in North American operations, where Aptar is subscale in indie brands and lost share with certain customers.
Russia deconsolidation
OOO Aptar Vladimir was placed under external administration on September 21, 2026, costing $61.2 million before tax including $30.0 million of inaccessible cash.
Input costs and pass-throughs
Middle East-related input costs and pass-throughs with no margin diluted Closures and Beauty margins in 2026.
Regulation and litigation
PFAS bans, EU PPWR and California packaging law, and litigation with ARS Pharmaceuticals and Nemera.

What leadership says

“Sales growth alone is not our objective. Our goal is to convert the strong demand for our products into more consistent profitability.”

Gael Touya, President and Chief Executive Officer · Q3 2026 earnings call, October 30, 2026

“I'm not satisfied with the performance of North America.”

Gael Touya, President and Chief Executive Officer · Q3 2026 earnings call, October 30, 2026, on Beauty

“We are not predicated on any one drug.”

Gael Touya, President and Chief Executive Officer · Q3 2026 earnings call, October 30, 2026

“Aptar is entering its next chapter from a position of strength.”

Stephan Tanda, President and Chief Executive Officer · Q2 2026 earnings call, July 31, 2026, his final call as CEO

Where a supplier can help

Operational excellence in Beauty
The North American Beauty transformation targets planning, efficiency, quality and supply chain, opening room for operations consulting, planning software and quality systems.
Injectables quality and automation
The Pharma pipeline priority, with Premia Precision's 100% automated vision inspection and Mumbai expansion, favours clean-room, inspection and automation suppliers.
Input-cost management
Input costs passed through with no margin point to value for procurement analytics, resin sourcing and indexation management.
Sustainable materials
PPWR and PFAS regulation and the sustainable packaging priority suggest demand for recycled resins, mono-material design and lifecycle assessment.
Shared services and ROIC
The focus on fixed costs through Global Business Service Centers fits finance, HR and IT shared-services providers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Aptar?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Aptar

What does Aptar do?

Aptar designs and manufactures dispensing, dosing and protection technologies such as nasal spray pumps, inhaler valves, injectable components, fragrance pumps and closures for pharma, beauty, food and beverage brands.

What is Aptar's revenue?

FY2025 net sales were $3.78 billion; Q3 2026 net sales were $1.02 billion, and nine-month 2026 sales were $3.03 billion.

How many employees does Aptar have?

Approximately 14,000 employees in approximately 20 countries.

Who leads Aptar?

Gael Touya became President and CEO on September 1, 2026, succeeding Stephan Tanda; Vanessa Kanu is CFO.

What is Aptar's strategy?

Profitable growth, execution and disciplined capital allocation, led by a Pharma pipeline targeting 7% to 11% long-term core growth and a turnaround of North American Beauty.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)